Oklo stock tumbles as Financial Times scrutinizes valuation
Investing.com -- Shares of Grifols fell 3.5% following news that Sanofi’s experimental therapy for Alpha-1 antitrypsin deficiency demonstrated positive results in Phase II clinical trials.
Sanofi’s recombinant AAT therapy, efdoralprin alfa (formerly INBRX-101), met all primary and secondary endpoints in its Phase II study. The treatment showed superiority to plasma-derived therapy and achieved normal functional AAT levels with less frequent dosing requirements of every 3-4 weeks.
While Sanofi’s study focused on measuring biochemical restoration through functional AAT levels, Grifols is taking a different approach with its SPARTA Phase III trial. The SPARTA study concentrates on clinical efficacy by measuring lung-tissue preservation via CT scans, which aligns with European Medicines Agency requirements.
Grifols is also working to enable bi-weekly dosing for its plasma-derived therapy, with a subcutaneous version in development to improve patient convenience.
The competitive threat from Sanofi’s new therapy represents a meaningful risk for Grifols, as Alpha-1 treatments account for over 10% of the company’s sales, estimated at more than €700 million, with over 70% of that exposure in the United States. Increased uptake of efdoralprin could potentially pressure both volumes and margins for Grifols’ existing treatments.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.